Post hoc analysis of GALACTIC-HF (8232 patients with HFrEF): omecamtiv mecarbil vs placebo showed a non-significant trend to fewer serious ventricular arrhythmias, cardiac arrest or sudden death (329 vs 377 events; HR 0.86, 95% CI 0.75-1.00; P=0.054).
Secondary analysisn = 8,232
Foà et al. Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial